Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig

European Journal of Pharmacology

Volumn 486, Issue 2, 2004, Pages 209-221

  Fossa, Anthony A ^a   Wisialowski, Todd ^a   Wolfgang, Eric ^a   Wang, Ellen ^a   Avery, Michael ^a   Raunig, David L ^a   Fermini, Bernard ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alternans; Arrhythmia; HERG; QT prolongation; Torsade de Pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; NEUROLEPTIC AGENT; POTASSIUM CHANNEL HERG; PROKINETIC AGENT; RISPERIDONE; TERFENADINE; VERAPAMIL;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; GUINEA PIG; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; MALE; NONHUMAN; PRIORITY JOURNAL; TORSADE DES POINTES;

EID: 1242328681     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.12.028     Document Type: Article

References (50)

1. Adam D.R., Powell A.O., Gordon H., Cohen R.J. Ventricular fibrillation and fluctuations in the magnitude of the repolarization vector. I.E.E.E. Comput. Cardiol. 1982;241-244.
2. Benet L.Z. Pharmacokinetics and metabolism of bepridil. Am. J. Cardiol. 55:1985;8C-13C.
3. Berger R.D., Kasper E.K., Baughman K.L., Marban E., Calkins H., Tomaselli G.F. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation. 96:1997;1557-1565.
4. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ. Res. 73:1993;379-385.
5. Bloomfield D.M., Cohen R.J. Repolarisation alternans. Malik M. Risk of Arrhythmia and Sudden Death. 2001;256-265 BMJ Book, London.
6. Boudinot F.D., Jusko W.J. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J. Pharm. Sci. 73:1984;774-780.
7. Chen P.S., Garfinkel A., Weiss J.N., Karagueuzian H.S. Spirals, chaos, and new mechanisms of wave propagation. Pacing Clin. Electrophysiol. 20:1997;414-421.
8. Conley R.R., Mahmoud R.A. Randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 158:2001;765-774.
9. De Clerck F., Van de Water A., D'Aubioul J., Lu H.R., van Rossem K., Hermans A., Van Ammel K. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam. Clin. Pharmacol. 16:2002;125-140.
10. Fenton F.H., Cherry E.M., Hastings H.M., Evans S.J. The APD restitution hypothesis revised: slope >1 does not always determine alternans and spiral wave breakup. P.A.C.E. 389:2003;. (abstract).
11. Franz M.R., Swerdlow C.D., Liem L.B., Schaefer J. Cycle length dependence of human action potential duration in vivo. J. Clin. Invest. 82:1988;972-979.
12. Fossa A.A., Depasquale M.J., Raunig D.L., Avery M.J., Leishman D.J. The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J.P.E.T. 202:2002;828-833.
13. Fujiki A., Tani M., Mizumaki K., Shimono M., Inoue H. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. J. Cardiovasc. Pharmacol. 23:1994;374-378.
14. Gilmour R.F. Jr., Chialvo D.R. Electrical restitution, critical mass and the riddle of fibrillation. J. Cardiovasc. Electrophysiol. 10:1999;1087-1089.
15. Gilmour R.F. Jr., Otani N.F., Watanabe M.A. Memory and complex dynamics in cardiac Purkinje fibers. Am. J. Physiol. 272:1997;H1826-H1832.
16. Gladziwa U., Bares R., Klotz U., Dakshinamurty K.V., Ittel T.H., Seiler K.-U., Sieberth H.-G. Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clin. Pharmacol. Ther. 50:1991;673-681.
17. Groh W.J., Shinn T.S., Engelstein E.E., Zipes D.P. Amiodarone reduces the prevalence of T wave alternans in a population with ventricular tachyarrhythmias. J. Cardiovasc. Electrophysiol. 10:1999;1335-1339.
18. Hondeghem L.M., Hoffman P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence and instability. J. Cardiovasc. Pharmacol. 41:2003;14-24.
19. Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 103:2001;2004-2013.
20. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J.A.M.A. 269:1993;1513-1518.
21. + current on the guinea pig action potential. Circ. Res. 84:1999;964-972.
22. 2+. Cell Physiol. 33:1993;C1434-C1438.
23. Kitamura H., Ohnishi Y., Okajima K., Ishida A., Galeano E.J., Adachi K., Yokoyama M. Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. J. Am. Coll. Cardiol. 39:2002;295-300.
24. Klingenheben T., Gronefeld G., Li Y.G., Hohnloser S.H. Effect of metoprolol and D,L-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. J. Am. Coll. Cardiol. 38:2001;2013-2019.
25. Koller M.L., Riccio M.L., Gilmour R.F. Dynamic restitution of action potential duration during electrical alternans and ventricular fibrillation. Am. J. Physiol. 275:1998;H1635-H1642.
26. Lande G., Maison-Blanche P., Fayn J., Ghadanfar M., Coumel P., Funck-Bretano C. Dynamic analysis of dofetilide-induced changes in ventricular repolarization. Clin. Pharmacol. Ther. 64:1998;312-321.
27. Leclercq J.F., Maison-Blanche P., Cauchemez B., Coumel P. Respective role of sympathetic tone and cardiac pauses in the genesis of 62 cases of ventricular fibrillation recorded during Holter monitoring. Eur. Heart J. 9:1988;1276-1283.
28. Lesko L.J., Benotti J.R., Alpert J.S., Brady P.M., McCue J.E., Weiner B.H., Ockene I.S. Pharmacokinetics of intravenous bepridil in patients with coronary disease. J. Pharm. Sci. 75:1986;952-954.
29. Locati E.H., Maison-blanche P., Dejode P., Cauchemez B., Coumel P. Spontaneous sequences of onset of Torsade de Pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J. Am. Coll. Cardiol. 25:1995;1564-1575.
30. Lu Y., Wang Z. Terfenadine block of sodium current in canine atrial myocytes. J. Cardiovasc. Pharmacol. 33:1999;507-513.
31. McTavish D., Goa K.L., Ferrill M. Terfenadine - an updated review of its pharmacological properties and therapeutic efficacy. Drugs. 39:1990;552-574.
32. Muller F.B., Ha H.R., Hotz H., Schmidlin O., Follath F., Buhler F.R. Once a day verapamil in essential hypertension. Br. J. Clin. Pharmacol. 21:1986;143S-147S.
33. Physicians' Desk Reference ® ©, Vascor (bepridil hydrochloride). The Medical Economics Company, 2002.
34. Pohjola-Sintonen S., Viitasalo M., Toivonen L., Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 45:1993;191-193.
35. Pratt C.M., Ruberg S., Morganroth J., McNutt B., Woodward J., Harris S., Ruskin J., Moye L. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am. Heart J. 131:1996;472-480.
36. Psychopharmacological Drug Advisory Committee (PDAC) 2000. FDA background document on Zeldox (PDAC) 0700.M01). Food and Drug Administration, Rockville, MD, USA.
37. Ravin D.S., Levenson J.W. Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother. 31:1997;867-870.
38. Reed-Hagen A.E., Tsuchiya M., Shimada K., Wentland J.-A., Obach R.S. Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites. Biopharm. Drug Dispos. 20(9):1999;429-439.
39. Rosenbaum D.S., Jackson L.E., Smith J.M., Garan H., Ruskin J.N., Cohen R.J. Electrical alternans and vulnerability to ventricular arrhythmias. N. Engl. J. Med. 330:1994;235-241.
40. Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., Denjoy I., Guicheney P., Breithardt G., Keating M.T., Towbin J.A., Beggs A.H., Brink P., Wilde A.A.M., Toivonen L., Zareba W., Robinson J.L., Timothy K.W., Corfield V., Wattanasirichaigoon D., Corbett C., Haverkamp W., Schulze-Bahr E., Lehmann M.H., Schwartz K., Coumel P., Bloise R. Genotype-phenotype correlation in the long-QT syndrome gene-specific triggers for life-threatening arrhythmias. Circulation. 103:2001;89-95.
41. Singh B.N., Nademanee K., Feld G., Piontek M., Schwab M. Comparative electrophysiologic profiles of calcium antagonist with particular reference to bepridil. Am. J. Cardiol. 55:1985;14C-19C.
42. van Haarst A.D., van't Klooster G.A.E., van Gerven J.M.A., Schoemaker R.C., van Oene J.C., Burggraaf J., Coene M.-C., Cohen A.F. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin. Pharmacol. Ther. 64:1998;542-546.
43. + channel human ether-a-go-go related gene (HERG) by macrolide antibiotics. J.P.E.T. 302:2002;320-327.
44. Walker M.L., Rosenbaum D.S. Repolarization alternans: implications for the mechanism and prevention of sudden cardiac death. Cardiovasc. Res. 57:2003;599-614.
45. Watanabe M.A., Koller M.L. Mathematical analysis of dynamics of cardiac memory and accommodation: theory and experiment. Am. J. Physiol., Heart Circ. Physiol. 282:2002;H1534-H1547.
46. Watanabe M.A., Fenton F.H., Evans S.J., Hasting H.M., Karma A. Mechanisms for discordant alternans. J. Cardiovasc. Electrophysiol. 12:2001;196-206.
47. Webster R., Allan G., Anto-Awuakye K., Harrison A., Kidd T., Leishman D., Phipps J., Walker D. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica. 31:2001;633-650.
48. Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. J.A.M.A. 269:1993;1532-1536.
49. Wysowski D.K., Corken A., Gallo-Torres H., Talarico L., Rodriguez E.M. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am. J. Gastroenterol. 96:2001;1698-1703.
50. Yan G.-X., Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation. 98:1998;1928-1936.